still amazes me how little mainstream coverage this stock gets...

still amazes me how little mainstream coverage this stock gets when you read about the results in regards to HIV treatment...

Biotron's BIT225 inhibits replication of virus in monocyte cells isolated from HIV patients



Singapore, December 17, 2009: The drug, developed by Sydney based Biotron Limited and known as BIT225 was tested in a study involving 18 HIV positive patients at Sydney’s St Vincent’s Hospital.

The drug was able to inhibit replication of the HIV virus in monocyte cells isolated from the HIV-infected patients, where until now, it has been able to 'hide' from current drug treatments. Monocytes collected from the patients were treated with BIT225 to see the effect of the drug on virus within the cells. The study says, BIT225 was able to stop the virus replicating in these storage cells by up to 99 per cent. Moreover, it was also able to stop the virus transferring to uninfected T Cells.

Dr John Wilkinson, senior virologist Biotron, speaking at the Fourth International Workshop on HIV Persistence During Therapy said, “In people infected with HIV, there is an ongoing cycle of infection of T Cells with HIV from reservoir cells and, at present, there is no drug that can target this process. Treatment and elimination of this reservoir remains a major therapeutic challenge. Even patients who have been treated with highly active anti-retroviral therapy can experience rapid virus rebound because of these virus reserves in reservoir cells. By specifically targeting HIV in reservoir cells, BIT225 offers the potential to stop this on-going cycle of infection.”

The release notes that as further international recognition of its approach to treatment of HIV, a manuscript describing BIT225's ability to inhibit HIV replication in reservoir cells has been published this week in a highly regarded international peer-reviewed scientific journal.

The company said it is now progressing protocols for a Phase Ib/IIa trial of BIT225 in HIV patients. This trial is in addition to the proposed Phase II trial of the same drug in patients infected with Hepatitis C virus (HCV).

Dr Wilkinson said the market potential of any drug capable of treating HIV infection is very large with the disease costing the $3.3 billion every year.


© BioSpectrum Bureau